Pleco Therapeutics receives FDA Orphan Drug Designation for PTX-252

Nijmegen, The Netherlands– 16th January 2024– The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of Acute Myeloid Leukaemia (AML)....
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials